Gaëtan De Rauglaudre

CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial

Benoît You, Patrick Robelin, Michel Tod et al. · Clinical Cancer Research · 2020 · 132 citations

Medicine, Oncology, Pharmacology +13

Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial

Laurence Gladieff, Annamaria Ferrero, Gaëtan De Rauglaudre et al. · Annals of Oncology · 2011 · 70 citations · Full text

Medicine, Oncology, Pharmacology +16

Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study

F. Joly, Djihane Ahmed-Lecheheb, Elsa Kalbacher et al. · Annals of Oncology · 2019 · 55 citations

Medicine, Gynecology, Oncology +10

[Cancers of unknown origin: 311 cases].

A Lortholary, Sophie Abadie‐Lacourtoisie, Olivier Guérin et al. · PubMed · 2001 · 32 citations

Veterinary Medicine, Oncology, Pathology +11

Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial

Gwénaël Ferron, Gaëtan De Rauglaudre, Stéphanie Bécourt et al. · Gynecologic Oncology · 2023 · 27 citations

Medicine, Gynecology, Oncology +14